<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d459">
    <sentence id="DDI-DrugBank.d459.s0" text="The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .">
        <entity id="DDI-DrugBank.d459.s0.e0" charOffset="18-24"
            type="brand" text="ENABLEX"/>
        <entity id="DDI-DrugBank.d459.s0.e1" charOffset="108-119"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d459.s0.e2" charOffset="122-133"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d459.s0.e3" charOffset="136-144"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d459.s0.e4" charOffset="147-156"
            type="drug" text="nelfinavir"/>
        <entity id="DDI-DrugBank.d459.s0.e5" charOffset="159-172"
            type="drug" text="clarithromycin"/>
        <ddi id="DDI-DrugBank.d459.s0.d0" e1="DDI-DrugBank.d459.s0.e0"
            e2="DDI-DrugBank.d459.s0.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d459.s0.d1" e1="DDI-DrugBank.d459.s0.e0"
            e2="DDI-DrugBank.d459.s0.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d459.s0.d2" e1="DDI-DrugBank.d459.s0.e0"
            e2="DDI-DrugBank.d459.s0.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d459.s0.d3" e1="DDI-DrugBank.d459.s0.e0"
            e2="DDI-DrugBank.d459.s0.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d459.s0.d4" e1="DDI-DrugBank.d459.s0.e0"
            e2="DDI-DrugBank.d459.s0.e5" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d459.s1" text="Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).">
        <entity id="DDI-DrugBank.d459.s1.e0" charOffset="29-35"
            type="brand" text="ENABLEX"/>
        <entity id="DDI-DrugBank.d459.s1.e1" charOffset="173-182"
            type="drug" text="flecainide"/>
        <entity id="DDI-DrugBank.d459.s1.e2" charOffset="185-196"
            type="drug" text="thioridazine"/>
        <entity id="DDI-DrugBank.d459.s1.e3" charOffset="202-226"
            type="group" text="tricyclic antidepressants"/>
        <ddi id="DDI-DrugBank.d459.s1.d0" e1="DDI-DrugBank.d459.s1.e0"
            e2="DDI-DrugBank.d459.s1.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d459.s1.d1" e1="DDI-DrugBank.d459.s1.e0"
            e2="DDI-DrugBank.d459.s1.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d459.s1.d2" e1="DDI-DrugBank.d459.s1.e0"
            e2="DDI-DrugBank.d459.s1.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d459.s2" text="The concomitant use of ENABLEX with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects.">
        <entity id="DDI-DrugBank.d459.s2.e0" charOffset="23-29"
            type="brand" text="ENABLEX"/>
        <entity id="DDI-DrugBank.d459.s2.e1" charOffset="42-63"
            type="group" text="anticholinergic agents"/>
        <ddi id="DDI-DrugBank.d459.s2.d0" e1="DDI-DrugBank.d459.s2.e0"
            e2="DDI-DrugBank.d459.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d459.s3" text="Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to effects on gastrointestinal motility.">
        <entity id="DDI-DrugBank.d459.s3.e0" charOffset="0-21"
            type="group" text="Anticholinergic agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d459.s4" text="Drug Laboratory Test Interactions Interactions between darifenacin and laboratory tests have not been studied.">
        <entity id="DDI-DrugBank.d459.s4.e0" charOffset="55-65"
            type="drug" text="darifenacin"/>
    </sentence>
</document>
